Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Breast Neoplasms 2 Hodgkin Disease 1 Hematopoietic and Lymphatic System Neoplasm 1 Graft vs Host Disease 1 Cholangiocarcinoma 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 115 fludarabine phosphate 67 Mycophenolic Acid 62 Etoposide 61 Peripheral Blood Stem Cell Transplantation 58 Tacrolimus 55 Melphalan 48 Filgrastim 48 Busulfan 48 Whole-Body Irradiation 47 Doxorubicin 46 Radiotherapy 42 fludarabine 38 Cyclosporine 38 Brentuximab Vedotin 38 Vinblastine 35 Granulocyte Colony-Stimulating Factor 35 Antilymphocyte Serum 30 Methotrexate 29 Dacarbazine 29 Gemcitabine 28 Rituximab 26 Nivolumab 25 Prednisone 24 Bleomycin 24 Vincristine 22 pembrolizumab 21 Carmustine 21 Cytarabine 20 thymoglobulin 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hodgkin Disease × axatilimab × Clear all

NCT05723055 2026-05-08

NAHL

University of Utah

Phase 2 Active not recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡